244 related articles for article (PubMed ID: 37041531)
1. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
3. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics.
Cohen PR; Kato SM; Erickson CP; Calame A; Kurzrock R
Dermatol Online J; 2022 Jan; 28(1):. PubMed ID: 35499412
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
6. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract][Full Text] [Related]
7. [Perivascular epithelioid cell tumor of urinary system: a clinicopathologic analysis of 21 cases].
Wang GW; Wang Y; Chen YX; Li Q; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):443-7. PubMed ID: 22932453
[TBL] [Abstract][Full Text] [Related]
8.
Wagner AJ; Ravi V; Riedel RF; Ganjoo K; Van Tine BA; Chugh R; Cranmer L; Gordon EM; Hornick JL; Du H; Grigorian B; Schmid AN; Hou S; Harris K; Kwiatkowski DJ; Desai NP; Dickson MA
J Clin Oncol; 2021 Nov; 39(33):3660-3670. PubMed ID: 34637337
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).
Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U
World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738
[TBL] [Abstract][Full Text] [Related]
10. TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review.
Purwar R; Soni K; Shukla M; Verma A; Kumar T; Pandey M
World J Surg Oncol; 2022 Mar; 20(1):62. PubMed ID: 35232443
[TBL] [Abstract][Full Text] [Related]
11. Medical treatment of advanced malignant perivascular epithelioid cell tumors.
Fabbroni C; Sbaraglia M; Sanfilippo R
Curr Opin Oncol; 2020 Jul; 32(4):301-306. PubMed ID: 32541317
[TBL] [Abstract][Full Text] [Related]
12. Malignant Perivascular Epithelioid Cell Tumor of the Uterus.
Dhanesar GK; Rengarajan H; Chakraborty B
Cureus; 2023 Jul; 15(7):e41685. PubMed ID: 37575749
[TBL] [Abstract][Full Text] [Related]
13. Pneumothorax caused by cystic and nodular lung metastases from a malignant uterine perivascular epithelioid cell tumor (PEComa).
Okamoto S; Komura M; Terao Y; Kurisaki-Arakawa A; Hayashi T; Saito T; Togo S; Shiokawa A; Mitani K; Kobayashi E; Kumasaka T; Takahashi K; Seyama K
Respir Med Case Rep; 2017; 22():77-82. PubMed ID: 28706850
[TBL] [Abstract][Full Text] [Related]
14. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
[TBL] [Abstract][Full Text] [Related]
15. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
16. PEComa: morphology and genetics of a complex tumor family.
Thway K; Fisher C
Ann Diagn Pathol; 2015 Oct; 19(5):359-68. PubMed ID: 26144278
[TBL] [Abstract][Full Text] [Related]
17. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
[TBL] [Abstract][Full Text] [Related]
18. Uterine PEComas: correlation between melanocytic marker expression and TSC alterations/TFE3 fusions.
Bennett JA; Ordulu Z; Pinto A; Wanjari P; Antonescu CR; Ritterhouse LL; Oliva E
Mod Pathol; 2022 Apr; 35(4):515-523. PubMed ID: 34131293
[TBL] [Abstract][Full Text] [Related]
19. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
Testa S; Bui NQ; Ganjoo KN
Cancer Res Commun; 2023 Jul; 3(7):1212-1223. PubMed ID: 37448552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
